RecruitingNot a traditional drug phaseobservationalRules rewrite

Not a traditional drug phase: testing Cohort 1: Dupilumab for COPD (Chronic Obstructive Pulmonary Disease)

The STRIDE Registry will measure the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD.

Official registry: https://clinicaltrials.gov/study/NCT07612878 · Sanofi · enrollment listed as 350

What this phase means

This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.

They plan to enroll about 350 people at 7 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry

Interventions: Cohort 1: Dupilumab, Cohort 2: usual care only

Primary outcome (registry wording): Participant Characteristics

Who it is for (from inclusion criteria)

Ages 40 Years to any
COPD patients who are newly referred to start dupilumab treatment
Standard of care spirometry performed concurrently with the baseline visit or within 90 days prior to the baseline visit

Who the registry excludes

Patients who have contraindication to dupilumab according to the United States Prescribing Information (USPI)
Any condition that, in the opinion of the Investigator, may interfere with the patient's ability to participate in the study, such as short life expectancy, or other comorbidities that can predictably prevent the patient from completing the schedule of assessments
Patients currently participating in any treatment clinical trial The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial

Public study contact (from the registry)

Trial Transparency Trial Transparency

800-633-1610 option 6

Contact-us@sanofi.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

7 listed

IU Health Pulmonology & Critical Care Medicine — Indianapolis, Indiana (recruiting)
University of Kansas — Lawrence, Kansas (recruiting)
Duke — Durham, North Carolina (recruiting)
Ohio State University — Columbus, Ohio (recruiting)
The Respire Institute — Houston, Texas (recruiting)
Activian Clinical Research — Kingwood, Texas (recruiting)
The Lung & Sleep Institute of North Texas — North Richland Hills, Texas (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseNew York, New York

Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies

This study wants to obtain biologic materials from the blood, airways and/or urine of normal individuals and individuals with lung disease. The normal are used to establish a set of normal ranges for various parameters.

NCT01776398 · Official ClinicalTrials.gov record · Weill Medical College of Cornell University

RecruitingNot a traditional drug phaseLumezzane, Brescia

Not a traditional drug phase: Maximal strenght training (MST) plus endurance training (ET) for Chronic Obstructive Pulmonary Disease

In the context of pulmonary rehabilitation of COPD patients, recent guidelines and metanalysis describe that Resistance Training (RT) can be successfully performed alone or in conjunction with Endurance Training (ET) without evidence of side effects. Maximal Strength Training (MST) is a kind of RT typically performed at \~85-90% of 1RM with maximal velocity to be developed in the concentric phase.

NCT03799354 · Official ClinicalTrials.gov record · Istituti Clinici Scientifici Maugeri SpA

RecruitingNot a traditional drug phaseClermont-Ferrand

Not a traditional drug phase: Development of a screening algorithm designed to determine a "dysmobility" profile in patients with chronic illness. for Joint Osteoarthritis

Chronic illness is a public health issue and mobility loss is frequent in this population. Among its' multiple physical and psychological consequences, increased mortality and cardiovascular morbidity seem the main concern.

NCT04375280 · Official ClinicalTrials.gov record · University Hospital, Clermont-Ferrand

FAQ about this NCT record

Is NCT07612878 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07612878?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07612878?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary